Immunotherapy unleashes the power of the immune system to fight cancer, but for some patients, immunotherapy doesn’t work. New research from investigators may help explain why.
When immune cells called T lymphocytes infiltrate malignant tumors, the genetic program of those T cells, and the developmental path they then follow, may affect their response to immunotherapy and predict overall patient survival, the researchers found. The results overturn the prevailing model of immune responses in melanoma and present different therapeutic approaches.
In the study, published May 9 in Cancer Cell, the investigators analyzed thousands of human tumor samples, plus individual human T cells across many datasets and tumor types, and compared them to many models of T cell behavior in response to infections, cancer and vaccines. They found that T cells either become stuck in an early activation state or develop into memory cells that are expanded by current immunotherapy approaches.
“The T cells don’t behave in a singular manner, but we can understand their behavior and model it in a way that can predict patient outcomes and overall survival,” said senior author , associate professor of dermatology and of dermatology in microbiology and immunology at Weill Cornell Medicine, and a practicing dermatologist for melanoma patients at NewYork-Presbyterian/Weill Cornell Medical Center.
Scientists have long known that the immune system can detect and eliminate tumor cells on its own, but this process sometimes breaks down, leading to the development of cancer. Previous data seemed to support a theory in which, once a tumor is established, T lymphocytes entering the tumor keep seeing and responding to tumor proteins until they become exhausted and unable to attack the cancerous cells.
That theory was used to explain the success of immune checkpoint blockade, a type of therapy that uses cellular signals to improve T cell responses, reawakening the T cells’ ability to attack and eliminate the tumor.
Some patients’ tumors don’t respond to immune checkpoint blockade, though. To figure out why, the team began looking at larger datasets and analyzing them more broadly than previous studies.
“We wanted to take an entirely agnostic, unbiased approach to trying to understand what happens to a T cell when it enters the tumor microenvironment,” said Anandasabapathy, who’s also a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine.
By using large programs of many genetic markers and multiple, simultaneous genomic strategies to categorize cell fates, Anandasabapathy and her collaborators were able to re-classify T cells in tumors, and better model how they develop. The results show that infiltrating T cells don’t all meet the same fate in every tumor.
In contrast to the standard view, a “failure to launch” beyond early activation and progress to the more mature memory cell type – and not exhaustion – appeared to be the problem. The enrichment of long-lived memory programs correlates strongly with overall survival and a successful response to immune checkpoint blockade therapy in melanoma.
In addition to predicting outcomes, the investigators hope to find ways to change them. Getting T cells past their failure to launch and inducing the formation of tumor-infiltrating memory T cells in patients who lack them, for example, could make non-responsive tumors sensitive to immune checkpoint blockade.
While the current work focused on malignant melanoma, the scientists also identified that similar phenomena likely underlie differences in patient T cell responses to other cancers, including kidney, bladder, prostate and liver.
“The power of the study is really in opening new avenues of discovery and suggesting more rational therapeutics,” said first author Abhinav Jaiswal, a doctoral candidate at Weill Cornell Graduate School of Medical Sciences in Anandasabapathy’s laboratory.
Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see Anandasabapathy’s profile.
Alan Dove is a freelance writer for Weill Cornell Medicine.
